64cu-dota-ecl1i
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 27, 2018 (NCT03492762)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 64-copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04537403 | Phase 1 | Oct 1, 2020 | Washington University in St. Louis |
| NCT04217057 | Phase 1 | Jan 31, 2020 | National Institutes of Health (NIH), Washington University in St. Louis |
| NCT03851237 | Phase 1 | Jan 2, 2019 | National Cancer Institute (NCI), Washington University in St. Louis |
| NCT05107596 | Phase 1 | Nov 24, 2018 | Washington University in St. Louis |
| NCT03492762 | Early Phase 1 (Phase 1) | Feb 27, 2018 | Washington University in St. Louis |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Washington University in St. Louis | Academic/Hospital | 5 | 5 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1